Julius Clinical

Julius Clinical is a health care and pharmaceutical startup founded in 2008 and headquartered in The Netherlands. The company manages global clinical drug trials with the objective of making a significant impact on medicine and people's lives, as highlighted by their slogan, "Julius Clinical manages global clinical drug trials that will have a major impact on medicine and make a real difference." The company's approach is characterized by a strong emphasis on science, flexibility, creativity, innovation, and skilled networks of investigators globally. It collaborates with leading pharmaceutical, biotech, medical device, and food companies, as well as academic investigators, to conduct clinical trials in therapeutic areas such as cardiology, diabetes, CNS, and infectious diseases. The latest investment in Julius Clinical came in the form of a Private Equity Round at 28 November 2023 from Ampersand Capital Partners. The substantial global reach and reputation of the company are facilitated by its internationally recognized academic leaders and personal links with peers worldwide. This extensive network enables the company to efficiently select high-performing sites for trials and maintain motivated investigators. In summary, Julius Clinical stands out as a company that combines scientific expertise with operational efficiency to deliver impactful results in the field of clinical trials.